Rigel Pharmaceuticals (RIGL) Cash Flow Statement

Click line-items for a historical chart and %

Net (loss) income
Depreciation and amortization	798K
Stock-based compensation expense	4.67M
Prepaid expenses and other current assets	1.25M
Other assets	130K
Accounts payable	-1.25M
Accrued compensation	-1.7M
Other accrued liabilities	-92K
Deferred revenue	-13.43M
Deferred rent and other long term liabilities	-3.94M
Net cash (used in) provided by operating activities
Purchases of available-for-sale securities
Maturities and sales of available-for-sale securities
Capital expenditures	-798K
Net cash used in investing activities
Payments on capital lease obligations
Net proceeds from issuances of common stock	22.22M
Net cash provided by financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents at beginning of period	43.46M
Cash and cash equivalents at end of period	25.95M
Interest paid

Entities mentioned with RIGL

View All Entities